China's start-up gene detection technology to help the tumor precision treatment research.

(Health Times reporter Mao Yuanyuan) Recently, at the 14th National Conference on Colorectal Cancer, the China Anti-Cancer Association Colorectal Cancer Professional Committee launched a ctDNA test to assess the sensitivity of local progression period rectal cancer new auxiliary chemotherapy.
understand that ctDNA refers to the tumor cell gene free in the blood circulation system, the study by The Beijing University Shougang Hospital President Professor Gu Jin team, Yan and (Beijing) Technology Co., Ltd. in the United Nations a number of tumor diagnosis and treatment centers, aimed at exploring the blood free DNA gene mutation and local progression period rectal cancer new auxiliary chemotherapy sensitivity, screening new molecular markers, better play the role of genetic detection technology for the precise guidance of tumor treatment.
" in clinical practice, some local progression period rectal cancer patients through the new auxiliary chemotherapy technology, can show that the tumor withdrawal effect is good, the prognosis is also significantly improved, but some patients tumor withdrawal effect is not obvious, and bear unnecessary adverse reactions to chemotherapy and surgical delay. Moreover, at present, there are no clear indicators to predict the sensitivity of radiation chemotherapy, after radiation, through imaging, enteroscope, tumor markers and physical examination and other means to determine the existence of tumors there is a large error. "The main person in charge of this research project, Shougang Hospital President Professor Gu Jin introduced.Professor
Gu Jin revealed that there is a close relationship between ctDNA and cancer chemotherapy, surgery and survival rates. The purpose of the study was to explore whether ctDNA testing could identify indicators that could predict the sensitivity of patients before they received chemotherapy, so that sensitive patients could be screened for radiation chemotherapy and direct surgery for patients who resist. The second is to find some indicators after the release of chemotherapy (preoperative) to determine whether the patient has reached full remission, this can screen out the patients who have reached full remission for "wait and see" treatment strategy, while the patient simply not fully remission for surgical excision treatment.
", "Through this kind of research, we hope to solve the problem that traditional chemotherapy treatment options cannot be evaluated and predicted, and help doctors predict the patient's outcome before conducting the new complementary chemotherapy treatment, and really play the role of 'precision medicine', which has important clinical significance." At the same time, patients get the most accurate drug guidance and personalized treatment plan, to achieve the best treatment results, improve the quality of life. Du Bo, founder of Yanhe Technology, said, "At present, genetic testing is very common in targeted therapy, the surprise of this study is to jump out of the limits, target the field of chemotherapy, to meet more clinical needs, is conducive to further broaden the path of domestic personalized medicine." "
.